AnaptysBio Statistics
Total Valuation
AnaptysBio has a market cap or net worth of $1.80 billion. The enterprise value is $1.78 billion.
Important Dates
The last earnings date was Tuesday, March 3, 2026, after market close.
| Earnings Date | Mar 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AnaptysBio has 28.75 million shares outstanding. The number of shares has increased by 1.33% in one year.
| Current Share Class | 28.75M |
| Shares Outstanding | 28.75M |
| Shares Change (YoY) | +1.33% |
| Shares Change (QoQ) | +8.01% |
| Owned by Insiders (%) | 2.94% |
| Owned by Institutions (%) | 66.06% |
| Float | 17.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.69 |
| Forward PS | 14.16 |
| PB Ratio | 47.23 |
| P/TBV Ratio | 48.46 |
| P/FCF Ratio | 91.95 |
| P/OCF Ratio | 91.54 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 36.78, with an EV/FCF ratio of 90.88.
| EV / Earnings | n/a |
| EV / Sales | 7.60 |
| EV / EBITDA | 36.78 |
| EV / EBIT | 37.21 |
| EV / FCF | 90.88 |
Financial Position
The company has a current ratio of 9.07, with a Debt / Equity ratio of 7.81.
| Current Ratio | 9.07 |
| Quick Ratio | 8.94 |
| Debt / Equity | 7.81 |
| Debt / EBITDA | 5.71 |
| Debt / FCF | 14.82 |
| Interest Coverage | 0.60 |
Financial Efficiency
Return on equity (ROE) is -24.49% and return on invested capital (ROIC) is 7.79%.
| Return on Equity (ROE) | -24.49% |
| Return on Assets (ROA) | 7.06% |
| Return on Invested Capital (ROIC) | 7.79% |
| Return on Capital Employed (ROCE) | 14.70% |
| Weighted Average Cost of Capital (WACC) | 8.60% |
| Revenue Per Employee | $2.26M |
| Profits Per Employee | -$127,231 |
| Employee Count | 104 |
| Asset Turnover | 0.55 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AnaptysBio has paid $164,000 in taxes.
| Income Tax | 164,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +267.21% in the last 52 weeks. The beta is 0.41, so AnaptysBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +267.21% |
| 50-Day Moving Average | 53.99 |
| 200-Day Moving Average | 36.39 |
| Relative Strength Index (RSI) | 58.17 |
| Average Volume (20 Days) | 594,614 |
Short Selling Information
The latest short interest is 5.37 million, so 18.67% of the outstanding shares have been sold short.
| Short Interest | 5.37M |
| Short Previous Month | 5.63M |
| Short % of Shares Out | 18.67% |
| Short % of Float | 31.09% |
| Short Ratio (days to cover) | 12.34 |
Income Statement
In the last 12 months, AnaptysBio had revenue of $234.60 million and -$13.23 million in losses. Loss per share was -$0.46.
| Revenue | 234.60M |
| Gross Profit | 98.63M |
| Operating Income | 47.90M |
| Pretax Income | -13.07M |
| Net Income | -13.23M |
| EBITDA | 48.46M |
| EBIT | 47.90M |
| Loss Per Share | -$0.46 |
Full Income StatementBalance Sheet
The company has $311.64 million in cash and $290.64 million in debt, with a net cash position of $21.00 million or $0.73 per share.
| Cash & Cash Equivalents | 311.64M |
| Total Debt | 290.64M |
| Net Cash | 21.00M |
| Net Cash Per Share | $0.73 |
| Equity (Book Value) | 37.21M |
| Book Value Per Share | 1.33 |
| Working Capital | 311.63M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $19.70 million and capital expenditures -$87,000, giving a free cash flow of $19.61 million.
| Operating Cash Flow | 19.70M |
| Capital Expenditures | -87,000 |
| Depreciation & Amortization | 559,000 |
| Net Borrowing | n/a |
| Free Cash Flow | 19.61M |
| FCF Per Share | $0.68 |
Full Cash Flow StatementMargins
Gross margin is 42.04%, with operating and profit margins of 20.42% and -5.64%.
| Gross Margin | 42.04% |
| Operating Margin | 20.42% |
| Pretax Margin | -5.57% |
| Profit Margin | -5.64% |
| EBITDA Margin | 20.65% |
| EBIT Margin | 20.42% |
| FCF Margin | 8.36% |
Dividends & Yields
AnaptysBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.33% |
| Shareholder Yield | -1.33% |
| Earnings Yield | -0.73% |
| FCF Yield | 1.09% |
Analyst Forecast
The average price target for AnaptysBio is $72.60, which is 15.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $72.60 |
| Price Target Difference | 15.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 16.30% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AnaptysBio has an Altman Z-Score of 0.46 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.46 |
| Piotroski F-Score | 6 |
